Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲

Total Page:16

File Type:pdf, Size:1020Kb

Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲ JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions. But even for significant increase in the rate of allergic patients truly allergic to penicillin, is the reactions; whereas administration of concern over cephalosporins justified? It cefprozil, cefuroxime, cefpodoxime, cef- depends on the specific agent. What is cer- tazidime, and ceftriaxone is not. tain is that a blanket dismissal of all Penicillin skin testing can accurately cephalosporins is unfounded. predict a penicillin-allergic reaction, but CORRESPONDENCE Michael E. Pichichero, MD, is not predictive for cephalosporin aller- University of Rochester The truth about the myth gy unless the side chain of the penicillin Medical Center, 601 Elmwood Despite myriad studies spanning decades or ampicillin testing reagent is similar to Avenue, Box 672, Rochester, and involving varied patient populations, the cephalosporin side chain being evalu- New York 14642. E-mail: Michael_pichichero@ results have not conclusively established ated. Patients who have a reaction to a urmc.rochester.edu that penicillin allergy increases the risk of penicillin or a cephalosporin that is not 106 VOL 55, NO 2 / FEBRUARY 2006 THE JOURNAL OF FAMILY PRACTICE JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 107 Cephalosporins can be prescribed safely for penicillin-allergic patients ▲ IgE mediated and not serious may receive ■ Results repeated courses of that antibiotic and True incidence of reactions related antibiotics. to cephalosporins This article provides a comprehen- The most frequent reactions to cephalo- sive review of the frequency of allergic sporins are non-pruritic, non-urticarial cross-reactivity between penicillin/amox- rashes, which occur in 1.0% to 2.8% of icillin and cephalosporin antibiotics, sup- patients;4–8 for most, the mechanism is idio- porting the recent American Academy of pathic and not a contraindication for Family Physicians evidence-based clinical future use.38 Retrospective studies suggest a practice guideline on treatment of acute 1% to 3% incidence of immune or allergic otitis media recommending the use of reactions to cephalosporins independent of cefuroxime, cefpodoxime, cefdinir, and any history of penicillin/amoxicillin ceftriaxone cephalosporins for patients allergy.31 Anaphylactic reactions from allergic to penicillin. cephalosporins are extremely rare, with the risk estimated at 0.0001% to 0.1%.31,38 A seminal study suggested approximately ■ Methods 0.004% to 0.015% of treatment courses We searched Medline and EMBASE data- with penicillin results in anaphylaxis.5,9–11 bases for English-language articles using Several studies suggest that cephalosporin- the keywords cephalosporin, penicillin, induced anaphylaxis occurs no more allergy, and cross-sensitivity for the years frequently among patients with known 1960 to 2005. Among 219 articles iden- penicillin allergy than among those with- tified, 101 were included as source mate- out such allergy.23,27,38–41 rial for this review. Articles we excluded were reviews, republication of results, or Determining cross-reactivity ones irrelevant to our purpose. Penicillins and cephalosporins both possess Five articles described the rate of a beta-lactam ring for antimicrobial activi- rashes following use of penicillin and ty. They differ in that the 5-membered cephalosporins,4–8 and 4 articles described thiazolidine ring of penicillin is replaced in FAST TRACK rates of anaphylaxis.5,9–11 We included 26 the cephalosporins with a 6-membered Penicillin articles for the evidence base evaluating dihydrothiazine ring. After degradation, penicillin/amoxicillin cross-allergy.3,12–36 penicillin forms a stable ring, whereas compounds Eleven articles relied on patient history of cephalosporins undergo rapid fragmenta- contaminated with penicillin/amoxicillin allergy to categorize tion of their rings.42 Immunologic cross- cephalosporins results and establish reaction rates and rel- reactivity between the penicillin and ative risks for the penicillin/amoxicillin cephalosporin beta-lactam rings is, there- led to the allergic vs nonallergic when receiving fore, very unlikely—an observation con- erroneous cephalosporins.12–15,17–20,27,28,31 Fourteen arti- firmed by monoclonal antibody analysis.43 assumption of 10% cles relied on patient history of How the “10% cross-reactivity” myth cross-reactivity penicillin/amoxicillin allergy plus skin test- took hold. When the first-generation ing results to penicillin/amoxicillin to cate- cephalosporins cephaloridine and cepha- gorize patients.16,21–25,29,30,32–37 One article3 lothin were introduced in the 1960s, aller- provided data on a subset where peni- gic and anaphylactic reactions were report- cillin/amoxicillin allergy was established ed in patients with previous allergic based on history, and a separate subset reactions to penicillins. Subsequent reports, where penicillin/amoxicillin allergy was which attributed up to 10% cross-reactivity established by skin testing. Other articles between the 2 drug classes, involved these related to antibiotic chemical structures, same first-generation cephalosporins plus animal studies, monoclonal antibody stud- cephalexin and cefadroxil and a second- ies, cross-reactive antibody studies, and generation drug, cefamandole. However, antibiotic skin testing were also reviewed. these studies were flawed because the www.jfponline.com VOL 55, NO 2 / FEBRUARY 2006 107 JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 108 APPLIED EVIDENCE penicillin test compounds had been contam- Many other studies have suggested inated with cephalosporins. Until 1982, that cross-reactive immune responses to penicillin was produced commercially using cephalosporins depend on side chain struc- the cephalosporium mold.38 ture;22,23,27,32,37,38,44–49 that is, cephalosporins Many recent studies have established with a 7-position side chain similar to ben- that the rate of cross-reactivity between zylpenicillin are more likely to cross-react penicillin and cephalosporins has been with penicillin (TABLE 2). Cephalosporins grossly overestimated. In fact, the rate of that share a similar 7-position or 3- cross-reactivity between penicillin/amoxi- position side chain are more likely to cross- cillin and second- or third-generation react with each other. cephalosporins is very low and may actual- ly be lower than that between penicillins Cephalosporin/penicillin and other classes of antibiotics.44 cross-reactivity The evidence for limited cross-reactivity. Few studies have evaluated whether A summary of publications evaluating patients with primary hypersensitivity to 38,846 children and adults with and with- cephalosporins will experience cross- out a history of penicillin allergy is present- reactivity with penicillin. Romano et al49 ed in TABLE 1. The database included 2435 conducted skin tests and RASTs in patients patients with a history of penicillin allergy with immediate allergic reactions to and 961 patients with a history of peni- cephalosporins to examine responses cillin allergy and positive skin-test results to other cephalosporins and to classic peni- for penicillin or amoxicillin (total peni- cillin determinants. About 1 in 5 patients cillin-allergic patients=3396). The allergic allergic to a cephalosporin reacted to reaction rate is compared with 34,047 penicillin determinants, while most had patients without a history of penicillin positive results to other cephalosporins allergy and 1403 patients without a histo- with the same or similar side-chains. ry of penicillin allergy and negative skin- test results for penicillin or amoxicillin Limitations of skin testing FAST TRACK (total penicillin-nonallergic patients=35,450). Penicillin skin testing in patients
Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • “Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics Against Gram
    ORIGINAL ARTICLE A Comparative In Vitro Sensitivity Study of “Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics against Gram- negative Bacterial Isolates from Intensive Care Unit Sweta Singh1, Chinmoy Sahu2, Sangram Singh Patel3, Abhay Singh4, Nidhi Yaduvanshi5 ABSTRACT Introduction: A rapid increase in multidrug-resistant (MDR) strains is being seen across the globe especially in the Southeast Asian region, including India. Carbapenems and colistin form the mainstay of treatment against gram-negative pathogens, especially extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates. However, due to increased resistance to carbapenems and toxicity of colistin, especially in intensive care units (ICUs), carbapenem-sparing antibiotics like ceftriaxone–sulbactam–EDTA (CSE) combination needs to be evaluated. Materials and methods: Bacterial isolates cultured from various clinical samples from all ICUs for a period of 9 months were evaluated. Bacterial identification was performed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and antibiotic susceptibility testing were performed by disk diffusion and E test method. Antibiogram of various antibiotics was noted. Extended-spectrum beta-lactamase- and MBL-producing bacteria were identified by phenotypic methods. Antibiotic sensitivity results of CSE were compared with the comparator drugs like colistin, carbapenems, and tigecycline in Enterobacteriaceae, Acinetobacter spp., and Pseudomonas spp. along with ESBL and MBL producers. Results: A total of 2,760 samples of blood, cerebrospinal fluid (CSF), respiratory samples, tissue, and pus were collected from ICUs with maximum isolates from pus (37%) followed by respiratory samples (31%) and blood (27%). Escherichia coli and Klebsiella pneumoniae were the predominant gram-negative pathogens accounting for 56% of the isolates followed by Acinetobacter spp.
    [Show full text]
  • Surgical Decolonization and Prophylaxis
    Surgical Decolonization and Prophylaxis SurgicalSurgical Decolonization Decolonization and Prophylaxis and Prophylaxis DECOLONIZATION DECOLONIZATION Nasal Screening Result Recommended Intervention Nasal Screening Result Recommended Intervention MRSA Negative • No decolonization required MSSAMRSA NegativeNegative • No decolonization required MSSA PositiveNegative • Intranasal mupirocin twice daily x 5 days MSSA Positive • Intranasal mupirocin twice daily x 5 days MRSA Positive • Intranasal mupirocin twice daily x 5 days, MRSA Positive AND• Intranasal mupirocin twice daily x 5 days, •ANDChlorhexidine bathing one day prior to surgery ANTIMICROBIAL• ChlorhexidinePROPHYLAXISbathing one day prior to surgery ANTIMICROBIAL PROPHYLAXIS CLINICAL CONSIDERATIONS • Preoperative dose-timing CLINICAL CONSIDERATIONS • PreoperativeWithin 60 minutesdose-timing of surgical incision WithinExceptions: 60 minutes vancomycin of surgicaland fluoroquinolones incision within 120 minutes of surgical incisionExceptions: vancomycin and fluoroquinolones within 120 minutes of surgical • Weightincision-based dosing • WeightCefazolin-based: 2 gm dosingfor patients <120 kg, and 3 gm for patients ≥120 kg Vancomycin:Cefazolin: 2 gm usefor ABW patients <120 kg, and 3 gm for patients ≥120 kg Gentamicin:Vancomycin: use use ABW ABW unless ABW is >120% of their IBW, in which case use AdjBWGentamicin:(see below use ABW for equation)unless ABW is >120% of their IBW, in which case use • DurationAdjBW of(see prophylaxis below for equation) • DurationA single of dose, prophylaxis
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Cefoperazone Sodium
    Disclaimer While these labels are the most current Drug Control Authority (DCA) approved versions of content, these are not necessarily reflective of final printed labeling currently in distribution LPD Title : Cefoperazone Sodium LPD Date : 07 February 2017 Country : Malaysia Reference : CDS version 5.0 dated 07 January 2017 Reason : Addition of adverse drug reactions (ADRs) Haemorrhage and Coagulopathy to Section 4.8 Undesirable effects, and also, addition of serious hemorrhage and coagulopathy to the warning about vitamin K deficiency in Section 4.4 Special warnings and precautions for use Addition of ADRs Anaphylactic reaction and Anaphylactic shock to Section 4.8 Undesirable effects Addition of ADR Dermatitis exfoliative to Section 4.8 Undesirable Effects and a warning statement on severe cutaneous adverse reactions (SCARs) to Section 4.4, Special warnings and precautions for use 1. NAME OF THE MEDICINAL PRODUCT CEFOBID 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Cefoperazone sodium is a semisynthetic broad-spectrum cephalosporin antibiotic for parenteral use only. Cefoperazone contains 34 mg sodium (1.5 mEq) per gram. Cefoperazone is a white crystalline powder which is freely soluble in water. The pH of a 25% aqueous solution is 5.0 to 6.5 and the solution is colorless to straw-yellow, depending on the concentration. The empirical formula is C25H26N9NaO8S2. 3. PHARMACEUTICAL FORM Cefoperazone sodium is available in vials containing 1 and 2 grams. Not For Distribution PFIZER CONFIDENTIAL Not all product strengths or pack sizes
    [Show full text]
  • Empiric Antimicrobial Therapy for Diabetic Foot Infection
    Empiric Antimicrobial Therapy for Diabetic Foot Infection (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2019) Infection Severity Preferred Empiric Regimens Alternative Regimens Comments Mild Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Outpatient management • Cellulitis less than 2 cm and • cephalexin 500 – 1000 mg PO q6h*,a OR • clindamycin 300 – 450 mg PO q6h (only if recommended ,a • cefadroxil 500 – 1000 mg PO q12h* severe delayed reaction to a beta-lactam) without involvement of deeper • Tailor regimen based on culture tissues and susceptibility results and True immediate allergy to a beta-lactam at MRSA Suspected: • Non-limb threatening patient response risk of cross reactivity with cephalexin or • doxycycline 200 mg PO for 1 dose then • No signs of sepsis cefadroxil: 100 mg PO q12h OR • cefuroxime 500 mg PO q8–12h*,b • sulfamethoxazole+trimethoprim 800+160 mg to 1600+320 mg PO q12h*,f Wound greater than 4 weeks duration:d Wound greater than 4 weeks duratione • amoxicillin+clavulanate 875/125 mg PO and MRSA suspected: q12h*,c OR • doxycycline 200 mg PO for 1 dose then • cefuroxime 500 mg PO q8–12h*,b AND 100 mg PO q12h AND metroNIDAZOLE metroNIDAZOLE 500 mg PO q12h 500 mg PO q12h OR • sulfamethoxazole+trimethoprim 800+160 mg to 1600/320 mg PO q12h*,f AND metroNIDAZOLE 500 mg PO q12h Moderate Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Initial management with • Cellulitis greater than 2 cm or • ceFAZolin 2 g IV q8h*,b OR • levoFLOXacin 750
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • Antimicrobial Surgical Prophylaxis
    Antimicrobial Surgical Prophylaxis The antimicrobial surgical prophylaxis protocol establishes evidence-based standards for surgical prophylaxis at The Nebraska Medical Center. The protocol was adapted from the recently published consensus guidelines from the American Society of Health-System Pharmacists (ASHP), Society for Healthcare Epidemiology of America (SHEA), Infectious Disease Society of America (IDSA), and the Surgical Infection Society (SIS) and customized to Nebraska Medicine with the input of the Antimicrobial Stewardship Program in concert with the various surgical groups at the institution. The protocol established here-in will be implemented via standard order sets utilized within One Chart. Routine surgical prophylaxis and current and future surgical order sets are expected to conform to this guidance. Antimicrobial Surgical Prophylaxis Initiation Optimal timing: Within 60 minutes before surgical incision o Exceptions: Fluoroquinolones and vancomycin (within 120 minutes before surgical incision) Successful prophylaxis necessitates that the antimicrobial agent achieve serum and tissue concentrations above the MIC for probable organisms associated with the specific procedure type at the time of incision as well as for the duration of the procedure. Renal Dose Adjustment Guidance The following table can be utilized to determine if adjustments are needed to antimicrobial surgical prophylaxis for both pre-op and post-op dosing. Table 1 Renal Dosage Adjustment Dosing Regimen with Dosing Regimen with CrCl Dosing Regimen with
    [Show full text]
  • Product Monograph
    Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Orbus Pharma Inc. Date of Preparation: February 25, 2009 20 Konrad Crescent Markham, Ontario Control #: 117041 L3R8T4 1 Product Monograph PrORB-CEFUROXIME Cefuroxime Axetil Tablets, USP 250 mg and 500 mg cefuroxime/tablet Antibiotic Actions and Clinical Pharmacology Cefuroxime axetil is an orally active prodrug of cefuroxime. After oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release cefuroxime into the blood stream. Conversion to cefuroxime, the microbiologically active form, occurs rapidly. The inherent properties of cefuroxime are unaltered after its administration as cefuroxime axetil. Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes referred to as penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis. This binding results in inhibition of bacterial cell wall synthesis and subsequent cell death. Specifically, cefuroxime shows high affinity for PBP 3, a primary target for cefuroxime in gram- negative organisms such as E. coli. Comparative Bioavailability Studies A two-way crossover, randomized, blinded, single-dose bioequivalence study was performed on 22 normal, healthy, non-smoking male subjects under fasting conditions. The rate and extent of absorption of cefuroxime axetil was measured and compared following a single oral dose (1 x 500 mg tablet)
    [Show full text]
  • The Efficacy of Cefmetazole Against Pyelonephritis Caused by Extended
    International Journal of Infectious Diseases 17 (2013) e159–e163 Contents lists available at SciVerse ScienceDirect International Journal of Infectious Diseases jou rnal homepage: www.elsevier.com/locate/ijid The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae a, b c d a,e Asako Doi *, Toshihiko Shimada , Sohei Harada , Kentaro Iwata , Toru Kamiya a Department of Infectious Diseases, Rakuwakai Otowa Hospital, Otowachinji-cho 2, Yamashina-ku, Kyoto, Japan b Department of General Internal Medicine, Nara City Hospital, Nara, Japan c Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Ota-ku, Tokyo, Japan d Division of Infectious Diseases, Kobe University Hospital, Chuo-ku, Kobe, Hyogo, Japan e Department of General Internal Medicine, Rakuwakai Otowa Hospital, Otowachinji-cho 2, Yamashina-ku, Kyoto, Japan A R T I C L E I N F O S U M M A R Y Article history: Objectives: Urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)- Received 3 April 2012 producing Enterobacteriaceae are on the increase. Although cefmetazole is stable in vitro against the Accepted 26 September 2012 hydrolyzing activity of ESBLs, no clinical study has ever evaluated its role in infections caused by these Corresponding Editor: William Cameron, organisms. We therefore evaluated the efficacy of cefmetazole compared to carbapenems against Ottawa, Canada pyelonephritis caused by ESBL-producing Enterobacteriaceae. Methods: A retrospective chart review was conducted at a tertiary care hospital from August 2008 to July Keywords: 2010. Chart reviews were done for patients with ESBL-producing organisms in urine identified in the Extended-spectrum beta-lactamase (ESBL) microbiology database.
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]